Skip to content

Detecting mitochondrial oxygen tension (mitoPO2) with the Cellular Oxygen Metabolism (COMET) measurement system as measure of local tissue oxygenation in patients with peripheral arterial disease – A pilot study

Detecting mitochondrial oxygen tension (mitoPO2) with the Cellular Oxygen Metabolism (COMET) measurement system as measure of local tissue oxygenation in patients with peripheral arterial disease – A pilot study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON22552
Enrollment
20
Registered
2021-10-27
Start date
2021-11-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral arterial occlusive disease (PAOD)

Interventions

None listed

Sponsors

University Medical Centre Groningen
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: - 55 years and older - Scheduled for a recanalization/bypass operation - Written informed consent. - Claudication, Rutherford class 4-6. - Healthy skin of the affected limb

Exclusion criteria

Exclusion criteria: - Insufficient knowledge of the Dutch language, illiteracy, or language barrier. - Lower leg fracture within the past 12 months. - (Partial) amputation of one of the feet and/or legs. - Tattoos in location of patches. - Severe cardiac-pulmonary failure. - Known hypersensitivity to the active substance or any of the following excipients: patches: acrylic pressure sensitive adhesive (poly[(2-ethylhexyl)acrylate-co-methylacrylate-co-acrylic acid-co-glycidylmethacrylate]), backing film: pigmented polyethylene aluminium vapor coated polyester, and release liner (polyethylene terephthalate film) which is removed prior to application. - Known diagnosis of porphyria. - Known photodermatoses of varying pathology and frequency, e.g. metabolic disorders such as aminoaciduria, idiopathic or immunological disorders such as polymorphic light reaction, genetic disorders such as xeroderma pigmentosum, and diseases precipitated or aggravated by exposure to sun light such as lupus erythematoides or phemphigus erythematoides. - Diabetes. - Previous photodynamic therapy or recent use of a tanning bed. - Subjects using medicinal products with known phototoxic or photoallergic potential such as St. John's wort, griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulphonamides, quinolones and tetracyclines. - Use of other topical medicinal products.

Design outcomes

Primary

MeasureTime frame
The feasibility and tolerability of mitochondrial oxygenation measurements with the COMET device and Alacare patch in patients with severe claudication (Rutherford class 4-6).

Secondary

MeasureTime frame
• the optimal measurement location for the measurement of mitochondrial oxygen consumption with the best signal quality. • the influence of application time for the Alacare patch on the signal quality. • correlation of the COMET device measurements to TcPO2 and ankle brachial index (ABI) • signal quality in the same place of the Alacare patch after previous use. • effect of skin temperature on COMET measurements

Contacts

Public ContactAbdallah Hussam Abdallah Zaid Al-Kaylani

University Medical Centre Groningen

a.h.a.zaid.al-kaylani@umcg.nl0687827217

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)